The COCOON trial compared SOC with prophylactic management for treatment-related dermatologic events with amivantamab plus lazertinib. In this Q&A, Dr. Martin F. Dietrich explains the prophylactic regimen’s impact on effects of the skin, scalp, and nails. APP Alyson Singer offers best practices for patient education. Read more
With many new lung cancer treatments approved through accelerated tracks based on early-phase (I/II) trial data, we have become increasingly aware of the lack of standards for disclosing toxicities when […] Read more
The relationship between cancer and thromboembolic events as been widely studied since 1895. As we know, venous thromboembolism (VTE) is a well-recognized complication of malignancy, including pulmonary embolism (PE), deep-vein […] Read more
The pandemic underscores unmet needs in critical care management and presents an opportunity for learning from patients with cancer. Read more
Approximately one-third of patients with NSCLC are diagnosed with stage III disease.1 Concurrent platinum-based chemotherapy with thoracic radiation (CRT) has been considered the cornerstone of treatment for patients with inoperable […] Read more
Two separate randomized phase III trials have established atezolizumab (IMpower1331 and durvalumab (CASPIAN2) as first-line treatments for extensive-stage (ES) SCLC in combination with chemotherapy followed by these same checkpoint inhibitors (CPIs) […] Read more
Multidisciplinary Tumor Boards: Integrating Best Patient Care and Education in Precision Medicine
+more
One of the pillars of organ-specific tumor centers certified by the German Cancer Society, such as lung, breast, and prostate cancer centers, is a weekly multidisciplinary tumor board (MTD). In […] Read more
The availability of effective TKIs for patients with metastatic NSCLC with targetable oncogenes such as EGFR, ALK, ROS1, and BRAF has transformed the treatment landscape, extending median expected OS from […] Read more
Using data from SEER databases, Howlader and colleagues recently reported that incidence-based mortality from NSCLC in men decreased from 6.3% annually (95% CI, 3.4 to 9.0) from 2013 through 2016, in contrast to the period […] Read more
Trial data can help inform change to standard of care, but at what point do we say enough data is enough and move forward with combination therapy as the new standard of care? Read more
As oncologists, we recognize that the patient–physician relationship is of utmost importance in establishing the patient’s trust in the physician and in the physician’s ability to learn more about the patient’s needs and perform accurate assessments for […] Read more